DK3630977T5 - Fremgangsmåder og sammensætninger til at fremme produktionen af proteiner indeholdende ikke-naturlige aminosyrer - Google Patents

Fremgangsmåder og sammensætninger til at fremme produktionen af proteiner indeholdende ikke-naturlige aminosyrer Download PDF

Info

Publication number
DK3630977T5
DK3630977T5 DK18734359.5T DK18734359T DK3630977T5 DK 3630977 T5 DK3630977 T5 DK 3630977T5 DK 18734359 T DK18734359 T DK 18734359T DK 3630977 T5 DK3630977 T5 DK 3630977T5
Authority
DK
Denmark
Prior art keywords
promoting
compositions
production
methods
amino acids
Prior art date
Application number
DK18734359.5T
Other languages
English (en)
Other versions
DK3630977T3 (da
Inventor
Sigeng Chen
Yingchun Lu
Feng Tian
Original Assignee
Ambrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambrx Inc filed Critical Ambrx Inc
Publication of DK3630977T3 publication Critical patent/DK3630977T3/da
Application granted granted Critical
Publication of DK3630977T5 publication Critical patent/DK3630977T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y601/00—Ligases forming carbon-oxygen bonds (6.1)
    • C12Y601/01—Ligases forming aminoacyl-tRNA and related compounds (6.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Reproductive Health (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK18734359.5T 2017-06-02 2018-06-02 Fremgangsmåder og sammensætninger til at fremme produktionen af proteiner indeholdende ikke-naturlige aminosyrer DK3630977T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762514754P 2017-06-02 2017-06-02
PCT/US2018/035764 WO2018223108A1 (en) 2017-06-02 2018-06-02 Methods and compositions for promoting non-natural amino acid-containing protein production

Publications (2)

Publication Number Publication Date
DK3630977T3 DK3630977T3 (da) 2024-04-15
DK3630977T5 true DK3630977T5 (da) 2024-09-02

Family

ID=62749186

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18734359.5T DK3630977T5 (da) 2017-06-02 2018-06-02 Fremgangsmåder og sammensætninger til at fremme produktionen af proteiner indeholdende ikke-naturlige aminosyrer

Country Status (23)

Country Link
US (2) US11851662B2 (da)
EP (2) EP3630977B1 (da)
JP (3) JP7245786B2 (da)
KR (3) KR102705871B1 (da)
CN (2) CN110959041B (da)
AU (1) AU2018275152B2 (da)
BR (1) BR112019025476A2 (da)
CA (1) CA3065137A1 (da)
DK (1) DK3630977T5 (da)
ES (1) ES2978044T3 (da)
FI (1) FI3630977T3 (da)
HR (1) HRP20240344T1 (da)
HU (1) HUE067136T2 (da)
IL (1) IL270906A (da)
LT (1) LT3630977T (da)
MX (2) MX2019014286A (da)
MY (1) MY202215A (da)
PL (1) PL3630977T3 (da)
PT (1) PT3630977T (da)
RS (1) RS65370B1 (da)
SI (1) SI3630977T1 (da)
SM (1) SMT202400125T1 (da)
WO (1) WO2018223108A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102705871B1 (ko) 2017-06-02 2024-09-11 암브룩스, 인코포레이티드 비천연 아미노산 함유 단백질 생성을 촉진하는 방법 및 조성물
SG11202009670RA (en) 2018-03-29 2020-10-29 Ambrx Inc Humanized anti-prostate-specific membrane antigen (psma) antibody drug conjugates
KR20210057124A (ko) 2018-09-11 2021-05-20 암브룩스, 인코포레이티드 인터류킨-2 폴리펩타이드 접합체 및 그의 용도
JP7560459B2 (ja) * 2018-12-21 2024-10-02 ジェネンテック， インコーポレイテッド アポトーシスに耐性のある細胞株を使用してポリペプチドを生成する方法
CN111117944B (zh) * 2019-11-22 2022-05-24 中农威特生物科技股份有限公司 一种用于规模化悬浮培养的抗凋亡mdck宿主细胞株及其建立方法
EP4172192A1 (en) * 2020-06-24 2023-05-03 Genentech, Inc. Apoptosis resistant cell lines
CN112375774A (zh) * 2020-10-26 2021-02-19 浙江新码生物医药有限公司 一种重组蛋白表达用工程菌株的构建方法
CN112575005A (zh) * 2021-01-04 2021-03-30 昆明理工大学 一种提高烟草重金属镉胁迫抗性和降低镉富集的方法
JP2024514222A (ja) * 2021-04-19 2024-03-28 ジェネンテック， インコーポレイテッド 改変された哺乳動物細胞
AU2023218678A1 (en) 2022-02-09 2024-08-01 Daiichi Sankyo Company, Limited Environmentally responsive masked antibody and use thereof
EP4511388A1 (en) * 2022-04-19 2025-02-26 F. Hoffmann-La Roche AG Improved production cells
JP2026504093A (ja) 2023-01-16 2026-02-03 アンブレツクス・インコーポレイテツド 抗ｃｄ７０抗体薬物コンジュゲート
WO2024241086A1 (en) 2023-05-24 2024-11-28 Ambrx, Inc. Pegylated bovine interferon lambda and methods of use thereof
EP4766404A1 (en) 2023-08-22 2026-07-01 Ambrx, Inc. Anti-PSMA ADC Conjugated Compositions and Their Methods of Use
WO2025147710A1 (en) * 2024-01-05 2025-07-10 Northwestern University Orthogonal translation systems and methods for identifying components thereof
WO2026058210A1 (en) * 2024-09-12 2026-03-19 Janssen Biotech, Inc. Model system and biomarkers to prevent lactate runaway
CN121652263B (zh) * 2026-02-06 2026-06-09 中国医学科学院北京协和医院 非天然氨基酸修饰的蛋白质及相关生物材料、制备方法和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2464532T3 (es) 2001-04-19 2014-06-03 The Scripps Research Institute Métodos y composiciones para la producción de pares ortogonales de ARNt-aminoacil-ARNt sintetasa
EP1583816A4 (en) 2002-12-22 2007-06-13 Scripps Research Inst PROTEIN ARRAYS
CN101160525A (zh) * 2003-06-18 2008-04-09 斯克利普斯研究院 非天然活性氨基酸遗传密码增加
JP5275566B2 (ja) 2003-06-18 2013-08-28 ザ スクリプス リサーチ インスティチュート 反応性非天然アミノ酸遺伝コード付加
JP4990792B2 (ja) 2004-12-22 2012-08-01 アンブレツクス・インコーポレイテツド アミノアシル−ｔＲＮＡシンテターゼの組成物およびこの使用
WO2007021297A1 (en) 2005-08-18 2007-02-22 Ambrx, Inc. COMPOSITIONS OF tRNA AND USES THEREOF
EP1951890A4 (en) * 2005-11-16 2009-06-24 Ambrx Inc PROCESSES AND COMPOSITIONS WITH NON-NATURAL AMINO ACIDS
KR101423898B1 (ko) 2005-12-14 2014-07-28 암브룩스, 인코포레이티드 비-천연 아미노산 및 폴리펩티드를 함유하는 조성물, 비-천연 아미노산 및 폴리펩티드를 포함하는 방법, 및 비-천연 아미노산 및 폴리펩티드의 용도
CN101511856B (zh) 2006-09-08 2016-01-20 Ambrx公司 脊椎动物细胞中抑制因子trna的转录
CN101528914B (zh) 2006-09-08 2014-12-03 Ambrx公司 通过脊椎动物细胞位点特异性并入非天然氨基酸
AU2007292892B9 (en) 2006-09-08 2013-02-28 Ambrx, Inc. Hybrid suppressor tRNA for vertebrate cells
CN101535338A (zh) 2006-10-18 2009-09-16 斯克利普斯研究院 在哺乳动物细胞中将非天然氨基酸遗传掺入蛋白质
WO2008127900A1 (en) * 2007-04-13 2008-10-23 The Salk Institute For Biological Studies Methods of genetically encoding unnatural amino acids in eukaryotic cells using orthogonal trna/synthetase pairs
TW200914043A (en) 2007-04-30 2009-04-01 Mj Biolog Inc PRRSV GP5 based compositions and methods
GB0721291D0 (en) * 2007-10-30 2007-12-12 Medical Res Council Methods and compositions
JP5763530B2 (ja) * 2008-06-10 2015-08-12 サンガモ バイオサイエンシーズ， インコーポレイテッド Ｂａｘ−およびＢａｋ−欠損細胞株の生成のための方法および組成物
WO2010141851A1 (en) * 2009-06-05 2010-12-09 Salk Institute For Biological Studies Improving unnatural amino acid incorporation in eukaryotic cells
EP2819702A4 (en) 2012-02-29 2015-05-20 Ambrx Inc NOVEL PRODRUGS WITH MOLECULE COMPOSITIONS AND ITS USES
EP3536700A1 (en) 2012-06-07 2019-09-11 Ambrx, Inc. Prostate-specific membrane antigen antibody drug conjugates
MX2014015205A (es) 2012-06-14 2015-08-14 Ambrx Inc Anticuerpos anti-psma conjugados a polipeptidos de ligando de receptor nuclear.
CN111499684B (zh) 2012-06-19 2024-10-22 Ambrx公司 抗cd70抗体药物结合物
GB201419109D0 (en) * 2014-10-27 2014-12-10 Medical Res Council Incorporation of unnatural amino acids into proteins
KR102705871B1 (ko) 2017-06-02 2024-09-11 암브룩스, 인코포레이티드 비천연 아미노산 함유 단백질 생성을 촉진하는 방법 및 조성물

Also Published As

Publication number Publication date
CN110959041A (zh) 2020-04-03
HRP20240344T1 (hr) 2024-05-24
US20210017527A1 (en) 2021-01-21
KR20240140174A (ko) 2024-09-24
FI3630977T3 (fi) 2024-04-24
MY202215A (en) 2024-04-17
JP7617162B2 (ja) 2025-01-17
SI3630977T1 (sl) 2024-05-31
KR20240063184A (ko) 2024-05-09
LT3630977T (lt) 2024-04-25
KR20200011979A (ko) 2020-02-04
AU2018275152A1 (en) 2020-01-16
MX2023004927A (es) 2023-05-17
JP2020522247A (ja) 2020-07-30
ES2978044T3 (es) 2024-09-04
WO2018223108A1 (en) 2018-12-06
BR112019025476A2 (pt) 2020-06-23
DK3630977T3 (da) 2024-04-15
EP3630977A1 (en) 2020-04-08
US12577575B2 (en) 2026-03-17
CA3065137A1 (en) 2018-12-06
SMT202400125T1 (it) 2024-05-14
JP2023075254A (ja) 2023-05-30
PL3630977T3 (pl) 2024-06-24
US11851662B2 (en) 2023-12-26
KR102705871B1 (ko) 2024-09-11
EP4382124A2 (en) 2024-06-12
RS65370B1 (sr) 2024-04-30
KR102662379B1 (ko) 2024-04-29
PT3630977T (pt) 2024-04-24
US20240167044A1 (en) 2024-05-23
CN110959041B (zh) 2023-09-29
AU2018275152B2 (en) 2025-01-23
EP4382124A3 (en) 2024-10-16
IL270906A (en) 2020-01-30
JP7245786B2 (ja) 2023-03-24
MX2019014286A (es) 2020-01-27
JP2025061014A (ja) 2025-04-10
HUE067136T2 (hu) 2024-10-28
CN117286182A (zh) 2023-12-26
EP3630977B1 (en) 2024-02-21
NZ760107A (en) 2024-03-22

Similar Documents

Publication Publication Date Title
DK3630977T3 (da) Fremgangsmåder og sammensætninger til at fremme produktionen af proteiner indeholdende ikke-naturlige aminosyrer
DK3601533T3 (da) Fremgangsmåder til frembringelse af tumorinfiltrerende lymfocytter og anvendelser af samme i immunoterapi
DK3303317T3 (da) Fremgangsmåder og sammensætninger til inhibering af interaktionen af menin med MLL-proteiner
EP3595699A4 (en) PEPTIDIC CONJUGATES OF CARTILAGE ECOTROPISM AND THEIR METHODS OF USE
DK3562503T3 (da) Polypeptid-antigen-konjugater med ikke-naturlige aminosyrer
DK3272867T3 (da) Anvendelse af programmerbare dna-bindingsproteiner til forbedring af målrettet genommodifikation
EP3576782A4 (en) COMPOSITIONS OF RECOMBINATION PRODUCT-PEPTIDE AND THEIR METHODS OF USE
DK3232806T3 (da) Opløsning af denatureret ærteprotein og anvendelser deraf til dannelse af mikropartikler
DK3298043T3 (da) SIRP-polypeptidsammensætninger og fremgangsmåder til anvendelse
DK3390444T3 (da) Anti-tl1a-antigenbindende proteiner og anvendelser deraf
DK3389636T3 (da) Sammensætninger og fremgangsmåder til fremstilling af proteinmikropartikler
DK3240895T3 (da) Sammensætninger og fremgangsmåder til proteinglykosylering
GB201419109D0 (en) Incorporation of unnatural amino acids into proteins
DK3649104T3 (da) Fremgangsmåde til fremstilling af langkædede aminosyrer og dibasiske syrer
DK3565579T3 (da) Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
DK3565828T3 (da) Sirp1 alpha-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
IL253971A0 (en) A method for purifying fusion proteins-albumin
DK3313864T3 (da) Rekombinante virusvektorer indeholdende prrsv minor protein og fremgangsmåder til fremstilling og anvendelse deraf
DK3818078T3 (da) Fremgangsmåder til fremstilling af rekombinante proteiner
MA53498A (fr) Production de protéines recombinantes
DK3774761T3 (da) Fremgangsmåde til fremstilling af substituerede cyclohexanaminosyreestere og spiroketalsubstituerede cykliske ketoenoler
DK3665133T3 (da) Fremgangsmåde og anlæg til fremstilling af cement
EP3906786C0 (en) METHOD FOR PREPARING SMALL PARTICLE-SIZED PROTEIN COMPOSITIONS
DK3331694T3 (da) Stort formet letvægtsmateriale og fremgangsmåde til fremstilling deraf
EP3377633C0 (en) PRODUCTION OF RECOMBINANT PROTEINS